Author

Brian B. Gowen

Utah State UniversityORCID 0000-0001-9113-2575Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Jonna B. WestoveriD· 2 shared Adam J. HumeiD· 1 shared Alexander M. HoltziD· 1 shared Andrea MarziiD· 1 shared Anna Marie PyleiD· 1 shared Ciara T. HuiD· 1 shared Corey W. Henderson· 1 shared Darrell N. KottoniD· 1 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Jonna B. WestoverORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Immunomodulatory RIG-I Agonist SLR14 Confers Protection Against a Range of Highly Pathogenic Negative Sense RNA viruses

Kristina Meier, Judith Olejnik, Joseline Velasquez-Reyes, Jonna B. Westover, Pushpinder Bawa, Elizabeth R. Wrobel, Corey W. Henderson, Pan Hu, Adam J. Hume, Alexander M. Holtz, Olga Fedorova, Gustavo Mostoslavsky, Darrell N. Kotton, John H. Connor, Andrea Marzi, , Elke Mühlberger

SLR14, an immunomodulatory RIG-I agonist, provides broad-spectrum antiviral protection against multiple highly pathogenic negative-sense RNA viruses in vitro and in vivo.

bioRxiv · Oct 10, 2026 · PreprintMicrobiology

Mutations that positively affect Bandavirus glycoprotein function on VSV vectored vaccines

Raegan J. Petch, Philip D. Hicks, Jonna B. Westover, Brian B. Gowen, Paul F. Bates

This paper identifies a mutation that enhances the efficacy of a VSV-based vaccine against SFTSV and develops a similar vaccine for HRTV, showing improved immune responses and protection.

Journal of Virology · Sep 24, 2026Peer-reviewedMicrobiology

SIRPA suppresses integrin-dependent virus endocytosis

Zhonghao Yan, Kruthika Raman Iyer, Minghao Li, Kie‐Hoon Jung, Ciara T. Hu, Natalia Ansin, Nicolás Sarute, Brian B. Gowen, Susan R. Ross

This study shows SIRPA inhibits integrin-dependent virus endocytosis by blocking a signaling pathway involving SHP2, SFKs, FAK, and alpha-integrin, offering therapeutic targets for RNA viruses.

bioRxiv · Apr 18, 2026 · PreprintCell Biology